[
    {
        "Sponsor": "TP Therapeutics--MET mutation",
        "NCT#": "NCT03993873",
        "Protocol Title": "A Phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics, efficacy and anti-tumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "TP Therapeutics--RET mutation",
        "NCT#": "NCT04161391",
        "Protocol Title": "A Phase 1/2 Study of TPX-0046, a Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Pfizer",
        "NCT#": "TBD",
        "Protocol Title": "Multicenter, Randomized, Open-label Phase 3 Trial of ARV-471\u00b1 GnRH analogue vs Investigator\u2019s Endocrine Treatment Choice \u00b1 GnRH analogue in Patients with Estrogen Receptor Positive, HER-2Negative Advanced Breast Cancer Whose Disease Progressed After One Prior CDK4/6 inhibitor plus Endocrine based Treatment for Advanced disease.",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Novartis",
        "NCT#": "TBD",
        "Protocol Title": "Ociperlimab combo with tislelizumab vs pembrolizumab plus chemo--1st line NSCLC",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Cerner Learning Health Network",
        "NCT#": "TBD",
        "Protocol Title": "Freenome Diagnostic Blood Tests for Cancer Screening",
        "Principal Investigator": "TBD"
    },
    {
        "Sponsor": "UCLA Stroke Network",
        "NCT#": "TBD",
        "Protocol Title": "CLARITY study for prevention of secondary stroke",
        "Principal Investigator": "Lance Lee, MD"
    },
    {
        "Sponsor": "Hologic",
        "NCT#": "TBD",
        "Protocol Title": "Multi-Center Prospective Non-Randomized Two-Arm Clinical Trial Evaluating Cryoablation for the Treatment of Stage 1 Invasive Breast Cancer in Lieu of Surgical Resection",
        "Principal Investigator": "Dennis Holmes, MD"
    },
    {
        "Sponsor": "xCures Vaccine study",
        "NCT#": "NA--Expanded Access Study",
        "Protocol Title": "\"Expanded access to neoantigen synthetic long peptide vaccine in an indivicual patient with advanced malignancy\"",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Stemline Therapeutics",
        "NCT#": "NCT05563220",
        "Protocol Title": "Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacastrant in Various Combination In Patients with Metastatic Breast Cancer (ELEVATE)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Veru MBC Phase III",
        "NCT#": "NCT04869943",
        "Protocol Title": "Randomized Phase 3 Efficacy Evaluation of Enobosarm Monotherapy vs Control Treatment of AR+/ER+/HER2- MBC in Patients With AR Nuclei Staining \u226540% Who Has Shown Disease Progression on a Nonsteroidal AI Fulvestrant and CDK 4/6 Inhibitor.",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Shionogi",
        "NCT#": "NCT05563220",
        "Protocol Title": "A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)",
        "Principal Investigator": "Lance Lee, MD"
    },
    {
        "Sponsor": "Philips",
        "NCT#": "NCT04451044",
        "Protocol Title": "Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.",
        "Principal Investigator": "Hambik Tankazyan, DO"
    }
]
